These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 38892150)

  • 1. Predicting Non-Alcoholic Steatohepatitis: A Lipidomics-Driven Machine Learning Approach.
    Mouskeftara T; Kalopitas G; Liapikos T; Arvanitakis K; Germanidis G; Gika H
    Int J Mol Sci; 2024 May; 25(11):. PubMed ID: 38892150
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatic lipidomic remodeling in severe obesity manifests with steatosis and does not evolve with non-alcoholic steatohepatitis.
    Ooi GJ; Meikle PJ; Huynh K; Earnest A; Roberts SK; Kemp W; Parker BL; Brown W; Burton P; Watt MJ
    J Hepatol; 2021 Sep; 75(3):524-535. PubMed ID: 33887358
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nonalcoholic fatty liver disease stratification by liver lipidomics.
    Vvedenskaya O; Rose TD; Knittelfelder O; Palladini A; Wodke JAH; Schuhmann K; Ackerman JM; Wang Y; Has C; Brosch M; Thangapandi VR; Buch S; Züllig T; Hartler J; Köfeler HC; Röcken C; Coskun Ü; Klipp E; von Schoenfels W; Gross J; Schafmayer C; Hampe J; Pauling JK; Shevchenko A
    J Lipid Res; 2021; 62():100104. PubMed ID: 34384788
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lipidomic identification of urinary extracellular vesicles for non-alcoholic steatohepatitis diagnosis.
    Zhu Q; Li H; Ao Z; Xu H; Luo J; Kaurich C; Yang R; Zhu PW; Chen SD; Wang XD; Tang LJ; Li G; Huang OY; Zheng MH; Li HP; Liu F
    J Nanobiotechnology; 2022 Jul; 20(1):349. PubMed ID: 35897102
    [TBL] [Abstract][Full Text] [Related]  

  • 5. LC-MS-based lipidomic analysis in distinguishing patients with nonalcoholic steatohepatitis from nonalcoholic fatty liver.
    Wang ZH; Zheng KI; Wang XD; Qiao J; Li YY; Zhang L; Zheng MH; Wu J
    Hepatobiliary Pancreat Dis Int; 2021 Oct; 20(5):452-459. PubMed ID: 34256994
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polyunsaturated fatty acid metabolites as novel lipidomic biomarkers for noninvasive diagnosis of nonalcoholic steatohepatitis.
    Loomba R; Quehenberger O; Armando A; Dennis EA
    J Lipid Res; 2015 Jan; 56(1):185-92. PubMed ID: 25404585
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolic signatures across the full spectrum of non-alcoholic fatty liver disease.
    McGlinchey AJ; Govaere O; Geng D; Ratziu V; Allison M; Bousier J; Petta S; de Oliviera C; Bugianesi E; Schattenberg JM; Daly AK; Hyötyläinen T; Anstee QM; Orešič M
    JHEP Rep; 2022 May; 4(5):100477. PubMed ID: 35434590
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lipidomics in non-alcoholic fatty liver disease.
    Kartsoli S; Kostara CE; Tsimihodimos V; Bairaktari ET; Christodoulou DK
    World J Hepatol; 2020 Aug; 12(8):436-450. PubMed ID: 32952872
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Irisin in patients with nonalcoholic fatty liver disease.
    Polyzos SA; Kountouras J; Anastasilakis AD; Geladari EV; Mantzoros CS
    Metabolism; 2014 Feb; 63(2):207-17. PubMed ID: 24140091
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lipidomic and transcriptomic analysis of western diet-induced nonalcoholic steatohepatitis (NASH) in female Ldlr -/- mice.
    Garcia-Jaramillo M; Spooner MH; Löhr CV; Wong CP; Zhang W; Jump DB
    PLoS One; 2019; 14(4):e0214387. PubMed ID: 30943218
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatic transcriptome signatures in patients with varying degrees of nonalcoholic fatty liver disease compared with healthy normal-weight individuals.
    Suppli MP; Rigbolt KTG; Veidal SS; Heebøll S; Eriksen PL; Demant M; Bagger JI; Nielsen JC; Oró D; Thrane SW; Lund A; Strandberg C; Kønig MJ; Vilsbøll T; Vrang N; Thomsen KL; Grønbæk H; Jelsing J; Hansen HH; Knop FK
    Am J Physiol Gastrointest Liver Physiol; 2019 Apr; 316(4):G462-G472. PubMed ID: 30653341
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lipidomic biomarkers and mechanisms of lipotoxicity in non-alcoholic fatty liver disease.
    Svegliati-Baroni G; Pierantonelli I; Torquato P; Marinelli R; Ferreri C; Chatgilialoglu C; Bartolini D; Galli F
    Free Radic Biol Med; 2019 Nov; 144():293-309. PubMed ID: 31152791
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circulating lipidomic alterations in obese and non-obese subjects with non-alcoholic fatty liver disease.
    Jung Y; Lee MK; Puri P; Koo BK; Joo SK; Jang SY; Lee DH; Jung YJ; Kim BG; Lee KL; Park TS; Kang KT; Ryu DH; Kang SW; Kim D; Oh S; Kim W; Hwang GS
    Aliment Pharmacol Ther; 2020 Nov; 52(10):1603-1614. PubMed ID: 32892365
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Concise review of lipidomics in nonalcoholic fatty liver disease.
    Béland-Bonenfant S; Rouland A; Petit JM; Vergès B
    Diabetes Metab; 2023 May; 49(3):101432. PubMed ID: 36781065
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lipidomic signatures discriminate subtle hepatic changes in the progression of porcine nonalcoholic steatohepatitis.
    Herrera-Marcos LV; Martínez-Beamonte R; Arnal C; Barranquero C; Puente-Lanzarote JJ; Lou-Bonafonte JM; Gonzalo-Romeo G; Mocciaro G; Jenkins B; Surra JC; Rodríguez-Yoldi MJ; Alastrué-Vera V; Letosa J; García-Gil A; Güemes A; Koulman A; Osada J
    Am J Physiol Gastrointest Liver Physiol; 2024 Apr; 326(4):G411-G425. PubMed ID: 38375587
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biomarkers and subtypes of deranged lipid metabolism in non-alcoholic fatty liver disease.
    Mato JM; Alonso C; Noureddin M; Lu SC
    World J Gastroenterol; 2019 Jun; 25(24):3009-3020. PubMed ID: 31293337
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mitochondrial dysfunction-related lipid changes occur in nonalcoholic fatty liver disease progression.
    Peng KY; Watt MJ; Rensen S; Greve JW; Huynh K; Jayawardana KS; Meikle PJ; Meex RCR
    J Lipid Res; 2018 Oct; 59(10):1977-1986. PubMed ID: 30042157
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lipidomics in Nonalcoholic Fatty Liver Disease: Exploring Serum Lipids as Biomarkers for Pediatric Nonalcoholic Fatty Liver Disease.
    Draijer LG; Froon-Torenstra D; van Weeghel M; Vaz FM; Bohte AE; Holleboom AG; Benninga MA; Koot BGP
    J Pediatr Gastroenterol Nutr; 2020 Oct; 71(4):433-439. PubMed ID: 32947564
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Application of Machine Learning Methods to Predict Non-Alcoholic Steatohepatitis (NASH) in Non-Alcoholic Fatty Liver (NAFL) Patients.
    Fialoke S; Malarstig A; Miller MR; Dumitriu A
    AMIA Annu Symp Proc; 2018; 2018():430-439. PubMed ID: 30815083
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Non-invasive diagnosis of non-alcoholic steatohepatitis and fibrosis with the use of omics and supervised learning: A proof of concept study.
    Perakakis N; Polyzos SA; Yazdani A; Sala-Vila A; Kountouras J; Anastasilakis AD; Mantzoros CS
    Metabolism; 2019 Dec; 101():154005. PubMed ID: 31711876
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.